文献速递心力衰竭与心肌病

射血分数降低心衰患者停用长期药物治疗的后果

Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2024-10-23

本文综述了射血分数降低心衰患者停用长期药物治疗后的临床效应,归纳出四种停药反应模式。多巴酚丁胺等药物停药后出现反跳性临床恶化,地高辛、SGLT2抑制剂等停药后疗效持续但临床恶化。现有证据提示多数心衰药物停药后数周内出现有意义的临床恶化,应避免治疗中断。

要点

  • 心衰药物停药反应分四种模式,地高辛和SGLT2抑制剂停药后疗效持续但临床恶化
  • 多数心衰药物停药后数周内出现临床恶化,应避免短期治疗缺口
  • 神经激素拮抗剂撤药后恶化的证据多为观察性研究,存在混杂因素

核心结论

  • 多数已评估的心衰药物停药后数周内出现有意义的临床恶化,当前强调启用基础药物的同时应同等重视避免治疗中断。

研究设计与样本

  • 综述性文章,总结心衰长期药物治疗停用后临床效应的现有证据,归纳出四种停药反应模式。

主要发现

  • 停药反应模式一:疗效丧失但停药后无观察到的变化,如哌唑嗪。
  • 停药反应模式二:疗效衰减或丧失伴停药后反跳性临床恶化,如硝普钠。
  • 停药反应模式三:不良治疗效应持续,停药后临床恶化,如米力农和氟司喹南。
  • 停药反应模式四:有利治疗效应持续,停药后临床恶化,如地高辛和SGLT2抑制剂。
  • 地高辛、利尿剂、SGLT2抑制剂及部分ACEI有说服力的疗效持续性证据;神经激素拮抗剂撤药后恶化的证据多为观察性研究且存在混杂。

关键数值与推荐

  • 地高辛、利尿剂、SGLT2抑制剂有说服力的疗效持续性证据,ACEI证据有限。

临床怎么用

  • 心衰治疗中应避免即使短期的治疗缺口,在启用基础药物的同时同等重视维持治疗连续性。

局限性

  • 神经激素拮抗剂撤药后临床恶化的现有证据多为观察性研究,因撤药常因临床原因导致明显混杂,难以解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is uncertainty regarding the clinical effects of discontinuation of drugs for heart failure after long-term use. The withdrawal of long-term treatment can follow 1 of 4 distinct patterns: 1) loss of on-treatment effect with no observed changes following discontinuation (eg, prazosin); 2) attenuation or loss of on-treatment effect with rebound clinical worsening following discontinuation (eg, nitroprusside); 3) persistence of deleterious on-treatment effect followed by clinical worsening after discontinuation (eg, milrinone and flosequinan); and 4) persistence of favorable on-treatment effect followed by clinical worsening after discontinuation (eg, digoxin and sodium-glucose cotransporter 2 inhibitors). Persuasive evidence for persistence of efficacy has been demonstrated for the use of digoxin, diuretic agents, sodium-glucose cotransporter 2 inhibitors, and (to a limited extent) for angiotensin-converting enzyme inhibitors. Available evidence for worsening of clinical status following the withdrawal of neurohormonal antagonists largely consists of observational studies. However, their findings are difficult to interpret because of considerable confounding related to the fact that drugs were withdrawn for clinical reasons, which represented a more important contributor to the poor outcome of these patients than the withdrawal of an effective drug. Nevertheless, the totality of available evidence points to a meaningful clinical deterioration within a few weeks following the withdrawal for most drugs that have been evaluated for the treatment of heart failure. These findings suggests that that our current emphasis on the implementation of foundational drugs needs to include an equally important emphasis to avoid even short-term gaps in treatment.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Talha, Butler, Packer, et al. Consequences of Discontinuing Long-Term Drug Treatment in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2024. PMID: 39453366. doi:10.1016/j.jacc.2024.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。